Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN8A | Q9UQD0 | 8/20 | 0.47 |
| ▸ | SCN1A | P35498 | 5/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5864755 | 0.88 | SCN8A (0.52) | SCN8ASCN1AP2RX3LMNARORC | |
| SCHEMBL5865184 | 0.86 | MALT1 (0.52) | SCN8AP2RX3RORC | |
| SCHEMBL5864864 | 0.85 | P2RX3 (0.44) | SCN8ASCN1AP2RX3RORC | |
| SCHEMBL5864923 | 0.84 | RORC (0.45) | SCN8ASCN1AKCNH2P2RX3LMNA | |
| SCHEMBL5865064 | 0.84 | RORC (0.48) | SCN8ASCN1AP2RX3LMNAHRH1 | |
| SCHEMBL5865143 | 0.84 | SCN8A (0.50) | SCN8ASCN1AP2RX3RORC | |
| SCHEMBL5864995 | 0.83 | RORC (0.49) | EGFRERBB2P2RX3LMNAHRH1 | |
| SCHEMBL5864754 | 0.82 | KDM4E (0.49) | SCN8ASCN1AP2RX3LMNARORC | |
| SCHEMBL5864748 | 0.81 | RORC (0.45) | SCN8ASCN1AP2RX3LMNARORC | |
| SCHEMBL5864981 | 0.81 | SCN8A (0.56) | SCN8ASCN1ANPC1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030138-B2 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2006-04-18 | — | — | US | disclosed |
| US-20040147555-A1 | Benzamidine derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-07-29 | — | — | US | disclosed |
| EP-1375482-A1 | BENZAMIDINE DERIVATIVE | Sankyo Company, Limited (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147555-A1 | Benzamidine derivatives | F9, F7, F2 | SCN8A 763/4885SCN1A 572/4885KCNH2 153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.